Mevion Medical Systems, which markets recently-approved proton radiation therapy systems to treat cancer, withdrew its plans for an initial public offering on Thursday.
Mevion had planned to use IPO proceeds to expand its manufacturing and distribution facilities and to further develop its proton therapy technology.
Primary shareholders include Caxton Associates, ProQuest Investments, Venrock Healthcare Partners and CHL Medical Partners.
The Littleton, MA-based company was founded in 2004 and booked $8 million in sales for the 12 months ended June 30, 2014. MEVI. Jefferies and Leerink Partners were set to be the joint bookrunners on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
